Jounce Therapeutics Inc

Jounce Therapeutics — Investor Presentation (August 2022)

34 slides from Jounce Therapeutics's investor presentation, Aug 30, 2022

  1. Slide 1: Jounce Therapeutics Corporate Presentation

    Jounce Therapeutics Corporate Presentation A NEXT GEN IMMUNOTHERAPY COMPANY AUGUST 2022 Exhib i t 99.1

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer 2 Various statements concerning our future expectations, plans and prospects, including without limitation, our expectations regarding financial guidance, operating expenses and capital expenditures, the timing, initiation, progress, results of and release of data for clinical trial

  3. Slide 3: The Jounce Difference

    Proven Management Team • Founded by IO pioneers: Nobel Coley Lasker Prize • Cash runway into Q1 2024 The Jounce Difference 3 * Out licensed to Gilead Sciences, Inc. (clinical trial sponsor) The right immunotherapy for the right patients Productive Translational Science Platform • Various immune cell

  4. Slide 4: The Challenge and Promise of IO Therapy

    The Challenge and Promise of IO Therapy Lessons Learned Define New Opportunities 4 *PD-(L)1i = PD-1 inhibitor or PD-L1 inhibitor • Tumor with PD-(L)1i* approval • Minority of pts benefit • Tumor with PD-(L)1i approval • Majority pts do not respond • Tumor with no PD-(L)1i approval • Little to no ben

  5. Slide 5: New Immune Cell Targets Are Needed For Next Gen IO

    New Immune Cell Targets Are Needed For Next Gen IO Extend benefit to more patients and realize IO market potential 5 2022 IO Market $44B* 2026 IO market $74B & growing* Next Gen IO T cell-focused • Durable benefit in minority of patients • Many tumor types unresponsive • Majority of combos are chemo

  6. Slide 6: The Core of Our Approach: Translational Science Platform

    Human Tumor Samples The Core of Our Approach: Translational Science Platform 6 *PD= Pharmacodynamic Translational Drug Discovery • Sustainable engine • Multiple immune cell types • Goal of new IND every 12 – 18 months Reverse Translational Analysis • Patients with clinical outcomes • PD* and predict

  7. Slide 7: Jounce Immunotherapy Pipeline

    DISCOVERY PROGRAMS LILRB1 (ILT2) Myeloid & Lymphoid Bi-Specifics (Not Disclosed) Diverse Immune Cell Types Other Targets (Not Disclosed) PD-(L)1i Resistance Mechanisms Jounce Immunotherapy Pipeline 7 * Formerly JTX-1811 now out-licensed to Gilead Sciences, Inc. Program Target Biology Discovery Precl

  8. Slide 8: Lead Macrophage Program: JTX-8064

    Lead Macrophage Program: JTX-8064 8

  9. Slide 9: JTX-8064: Potential Macrophage Checkpoint Inhibitor

    JTX-8064: Potential Macrophage Checkpoint Inhibitor LILRB2 / ILT4 Target • LILRB2 is expressed on immunosuppressive macrophages • Immunosuppressive macrophages are a negative prognostic factor for many cancer types • Inhibition of LILRB2 reprograms macrophages to an immune active state and activates

  10. Slide 10: LILRB2 (ILT4) May Inhibit Response to PD-(L)1i Therapy

    LILRB2 (ILT4) May Inhibit Response to PD-(L)1i Therapy 10 • CD163 is a general marker for immunosuppressive macrophages • Similar associations between OS and CD163 have been reported for most tumor types in INNATE High LILRB2 / IFNγ Signature Ratio Correlates With Poor Response to PD- (L)1i Treatmen

  11. Slide 11: JTX-8064 Inhibits A Unique Macrophage Checkpoint LILRB2 (ILT4)

    JTX-8064 Inhibits A Unique Macrophage Checkpoint LILRB2 (ILT4) Proposed mechanism of action 11 Potential to Reverse PD-(L)1i Resistance JTX-8064 Immunosuppressive Macrophage (M2-like) Immune Activated Macrophage (M1-like) • Cytokine Production • Antigen Presentation • T-cell Activation

  12. Slide 12: JTX-8064 Reprograms Macrophages to Enhance T Cell Responses

    JTX-8064 Reprograms Macrophages to Enhance T Cell Responses 12 1. Cohen et al., Abstract 5007, AACR 2019; 2. McGrath et al., Abstract 1727, AACR 2021. JTX-8064 reprogrammed macrophages are more effective at stimulating T cells in co-culture2 Reprogramming of macrophages from M2 to an M1 state throug

  13. Slide 13: Translational Informatics Defined Initial Tumor Types

    Translational Informatics Defined Initial Tumor Types Higher Lower • Relative evaluation and ranking across all TCGA indications • Focus on 3 key RNA measures (LILRB2, Jounce TAM signature, IFNγ signature) • Figure sorted by LILRB2 13 TUMOR TYPE Testicular Cancer Mesothelioma Renal Cancer (clear cel

  14. Slide 14: JTX-8064: INNATE Study Designed to Rapidly Demonstrate POC

    Mono (n=22) & Combo (n=9) Dose Escalation Completed  JTX-8064: INNATE Study Designed to Rapidly Demonstrate POC Preliminary Clinical Data by Year End 2022 • Full receptor occupancy at 300mg • 700mg RP2D* • No DLTs** (up to 1200mg) 14 Combo expansions • Ovarian (3/4L) • HNSCC (1L) • Sarcoma (2-4L) •

  15. Slide 15: JTX-8064: INNATE Three Categories of Patients

    JTX-8064: INNATE Three Categories of Patients Mechanistic potential to improve effectiveness of T cell-directed therapies 15 3/4L Ovarian Cancer (Mono & Combo) No Approved PD-(L)1i (IO Naïve Patients) 1L Head and Neck Squamous Cell Carcinoma Approved PD-1i (IO Naïve Patients) 2/3L clear cell Renal C

  16. Slide 16: High Unmet Need in INNATE Indications

    High Unmet Need in INNATE Indications * Clinical trial patients who received PD-(L)1i treatment beyond RECIST progression (PD-(L)1i as last prior therapy) References: 1 Gandara et al. Journal of Thoracic Oncology 2018; Kazandjian et al. Seminars in Oncology 2017; 2 Haddad et al. Cancer 2019; 3 Escud

  17. Slide 17: JTX-8064: Anticipated INNATE Study Data in 2022

    JTX-8064: Anticipated INNATE Study Data in 2022 Mono and Pimivalimab Combo Dose Escalation and Expansion 17 Preliminary Clinical Data by Year End  At least 80 Phase 2 patients  Complete mono and combo dose escalation data  Preliminary mono and combo expansion cohort data  Data from stage 1 of Si

  18. Slide 18: Vopratelimab

    Vopratelimab 18

  19. Slide 19: Vopratelimab Biological Activity Distinct from CD8 Focused PD-(L)1i

    Vopratelimab Biological Activity Distinct from CD8 Focused PD-(L)1i • Vopra is an IgG1 agonist antibody selective for ICOS (inducible co-stimulatory of T cells) • Activates CD4 T cells that have been primed by antigen presentation Clinical Learnings to Date • Well tolerated at all doses tested alone

  20. Slide 20: SELECT: Randomized Phase 2 Predictive Biomarker Study

    SELECT: Randomized Phase 2 Predictive Biomarker Study Clinical Study of Two Wholly Owned Antibodies with New Predictive Biomarker Phase 2 SELECT Randomized POC Study • Novel predictive biomarker approach – (TISvopra) RNA signature • IO naïve 2L NSCLC in 69 patients selected with TISvopra • Designed

  21. Slide 21: SELECT Trial Top Line Results

    SELECT Trial Top Line Results (ICR*; FAS) • Vopra continues to remain well tolerated and had no new safety signals • Expected differentiated pulsatile dosing was achieved 21 • Mean percent change from baseline in tumor size in all measurable lesions, averaged over 9 and 18 weeks • Continuous variabl

  22. Slide 22: SELECT Trial Summary: RECIST Response & PFS

    22 *ICR = Independent Central Review; **Disease Control Rate or DCR = CR + PR + SD of at least 9 weeks; Data cut date: 07 July 2022 JTX-4014 (pimi) (N=36) pimi + vopra 0.1 mg/kg (N=18) pimi + vopra 0.03 mg/kg (N=15) Overall response rate n (%) (95% CI) 9 (25.0) (12.12, 42.20) 3 (16.7) (3.58, 41.42)

  23. Slide 23: SELECT Summary and Vopra Next Steps

    SELECT Summary and Vopra Next Steps 23 • SELECT results do not support moving into registration studies as had been our previous goal and we expect to re-evaluate vopra in the context of our broader pipeline in the coming months • SELECT: Trends in improved mean tumor change over 9 and 18 weeks, ove

  24. Slide 24: Pimivalimab PD-1 inhibitor

    Pimivalimab PD-1 inhibitor 24

  25. Slide 25: Pimivalimab (Pimi): PD-1 Inhibitor in POC Combo Studies

    Pimivalimab (Pimi): PD-1 Inhibitor in 2 POC Combo Studies Well-Characterized PD-1 Antibody, Fully Human IgG4 Phase 2 SELECT Monotherapy Results • 9/36 (25.0%) overall response rate • Well tolerated Phase 1 Study Results* • 3/18 (16.7%) confirmed responses • No deaths or dose limiting toxicities Oppo

  26. Slide 26: Discovery

    Discovery 26

  27. Slide 27: Jounce's Translational Science Platform

    Jounce’s Translational Science Platform Deconstructing the Tumor Microenvironment to Identify Novel Therapeutics 27 T cell Identify targets uniquely tied to cell types of interest Profile human tumors for target expression on cell types of interest More IO Responsive Less IO Responsive Targets for l

  28. Slide 28: JTX-1484 (Anti-LILRB4) Development Program

    JTX-1484 (Anti-LILRB4) Development Program New addition to our differentiated cell type strategy 28 • Expressed on immuno-suppressive myeloid cells in the TME, including MDSCs, tolerogenic DCs and M2-like macrophages • Potent and specific blocker of human LILRB4 with favorable PK, pre-clinical safet

  29. Slide 29: JTX-1484 (Anti-LILRB4): New Development Program

    JTX-1484 (Anti-LILRB4): New Development Program Proposed mechanism of action 29

  30. Slide 30: Milestones & Financials

    Milestones & Financials 30

  31. Slide 31: Upcoming Milestones

    Vopratelimab (SELECT): Top-line results reported • Plan to submit full data clinical abstract to ESMO-IO in December 2022 • Safety and preliminary efficacy data • Performance of biomarker JTX-1484 (LILRB4): • Continue to advance towards a 2023 IND Discovery: • Continue to advance multiple new target

  32. Slide 32: Financial Strength and Flexibility

    Financial Strength and Flexibility NASDAQ: JNCE Strong Balance Sheet • Cash runway into Q1 2024 • Excludes any potential milestone payments • $162.3M in cash, cash equivalents and investments, as of June 30, 2022 Cash Guidance • 2022 gross cash burn $115M - $130M Common Stock Outstanding • 51.7M sha

  33. Slide 33: The Jounce Difference

    The Jounce Difference 33 Opportunity Compelling Pipeline Upcoming Catalysts Financial Strength Clinical data expected by year end from both lead programs Next generation IO with discovery across a variety of different immune cell types leading to an extensive pipeline Multiple large market opportuni

  34. Slide 34: Jounce Therapeutics

    Jounce Therapeutics JOUNCETX.COM 34

Jounce Therapeutics — Investor Presentation (August 2022) on 6ix